GlassScriptPhysician profile
Rita Lap Kee Wang
NPI 1710984364
$2,150.04
in general payments reported to CMS, 2019-2025
31 companies · $292 in 2025
The $292 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $336 · 2021: $298 · 2022: $230 · 2023: $197 · 2024: $299 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $380.94 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Tris Pharma INC | $317.87 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $199.69 | 2019-2024 | |
| Glaxosmithkline, LLC. | $178.31 | 2019-2023 | Pediarix, Bexsero, Shingrix |
| Pfizer INC. | $163.14 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $161.76 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $67.75 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.78 | 2019-2021 | |
| Lilly USA, LLC | $47.41 | 2021-2022 | |
| Amarin Pharma, INC. | $42.93 | 2021 | |
| Supernus Pharmaceuticals, INC. | $41.65 | 2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $41.13 | 2023-2024 | Quviviq |
| Myovant Sciences INC. | $40.75 | 2022 | |
| Sobi, INC | $39.42 | 2019-2020 | |
| Hologic Sales and Service, LLC | $36.45 | 2020-2025 | Aptima |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $34.60 | 2023 | |
| Kaleo, INC. | $33.24 | 2019 | |
| Abbvie INC. | $33.23 | 2021-2022 | |
| Corium, LLC | $26.97 | 2023-2024 | Azstarys |
| Sanofi Pasteur INC. | $23.77 | 2021 | |
| Shire North American Group INC | $23.64 | 2019 | |
| Seqirus USA INC | $21.89 | 2024 | Flucelvax |
| Medtronic, INC. | $20.51 | 2022 | |
| Exeltis, USA INC. | $20.46 | 2024 | Slynd |
| Astrazeneca Pharmaceuticals LP | $17.95 | 2020 | |
| Novo Nordisk INC | $17.02 | 2022 | |
| Sage Therapeutics, LLC | $16.00 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $14.48 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.64 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.